Date: 2012-11-05
Type of information: Grant
Company: Glide Pharma (UK)
Investors: Biomedical Catalyst Fund (UK)
Amount: £2.3 Million (€ 2.88 million)
Funding type: grant
Planned used: The funds will be used to support the development of a novel formulation of teriparatide (parathyroid hormone) for the treatment of osteoporosis. The programme will include full pre-clinical development, and will incorporate formulation and manufacturing process development of the novel solid dose for administration with Glide Pharma’s needle-free delivery system.
Others: Glide Pharma, a specialty pharmaceutical company focused on the easy, safe and convenient administration of solid dose formulations of therapeutics and vaccines,has announced that the UK Biomedical Catalyst has awarded the company £2.3 million ($3.7 million) to support the development of a novel formulation of teriparatide (parathyroid hormone) for the treatment of osteoporosis. The award was announced by Technology Strategy Board and is one of 32 projects awarded funding totalling £39 million. These are the first substantial awards made from the £ 180 million Biomedical Catalyst programme managed by the Technology Strategy Board and the Medical Research Council.
Therapeutic area: Bone diseases
